Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease
S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - jamanetwork.com
Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that
occur with treatment with aducanumab, an amyloid-β (Aβ)–targeting monoclonal antibody, in
patients with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease
dementia. Objective To describe the radiographic and clinical characteristics of ARIA that
occurred in EMERGE and ENGAGE. Design, Setting, and Participants Secondary analysis of …
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that
occur with treatment with aducanumab, an amyloid-β (Aβ)–targeting monoclonal antibody, in
patients with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease
dementia. Objective To describe the radiographic and clinical characteristics of ARIA that
occurred in EMERGE and ENGAGE. Design, Setting, and Participants Secondary analysis of …